Castle Biosciences
Castle Biosciences Q4 Revenues up 31 Percent
The company saw a boost in testing volume in the fourth quarter, but not across all its assays, while full-year revenues grew 51 percent.
Preliminary Earnings Roundup: Natera, Guardant Health, Exact Sciences, CareDx, GeneDx, More
Several molecular diagnostics firms reported fourth quarter and full-year 2024 revenues and other business updates ahead of the annual JP Morgan Healthcare Conference this week.
CMS Contractors Novitas, FCSO Finalize Non-Coverage Decisions for Certain Cancer Genetic Tests
Tests from Castle Biosciences, Pacific Edge Diagnostics, Interpace Biosciences, Clinical Genomics, and the University of Pittsburgh Medical Center will no longer be covered.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
GenomeWeb Top 40 Drops 7 Percent in October, Outpacing Decline in Broader Market
The Dow Jones Industrial Average fell 1 percent, the Nasdaq fell less than 1 percent, and the Nasdaq Biotech Index declined 2 percent.